Insight Genetics has a number of ongoing research studies to advance the clinical understanding of Insight TNBCtype.
- In silico proof-of-concept studies have shown agreement with expected results in all scenarios tested to date. More information can be found here.
- Clinical studies with key opinion leaders
Insight Genetics also has a keen interest in the following therapeutic research areas and is looking for unique opportunities to collaborate.
- PARP inhibitors (Basal-like subtypes)
- mTOR/PI3K Inhibitors (Mesenchymal subtypes)
- Androgen Receptor Therapies (LAR subtype)
- Immuno-Oncology Therapies (IM modifier)